Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American...
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American...
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions
阿瑪琳公司宣佈，調查人員將在美國心臟協會科學會議上展示來自REDUCE-It結果試驗的患有和沒有冠狀動脈疾病史的患者的額外亞組分析，以及關於二十碳五烯酸（EPA）的機械數據
Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association's Scientific Sessions, November 16-18, 2024 in Chicago, IL.
美國阿瑪琳公司plc（納斯達克代碼：AMRN）今日宣佈，調查人員將在2024年11月16日至18日於伊利諾伊州芝加哥舉行的美國心臟協會科學會議上展示來自里程碑式REDUCE-It結果試驗的患有和沒有冠狀動脈疾病（CAD）史的患者的額外亞組分析，以及關於二十碳五烯酸（EPA）的機械數據
"The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA/VAZKEPA (icosapent ethyl), not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date," said Steve Ketchum, PhD, Chief Scientific Officer at Amarin. "Data presented at AHA will showcase new evidence from the REDUCE-IT CAD subanalysis, highlighting the benefits of VASCEPA/VAZKEPA in secondary prevention patients, with and without CAD history."
"在AHA科學會議上展示的數據繼續證實了VASCEPA/VAZKEPA（20碳乙酯）在整體REDUCE-It試驗人群以及迄今爲止分析過的各種亞組中的臨床效用和價值，"阿瑪琳公司首席科學官史蒂夫·凱徹姆博士表示。"在AHA上展示的數據將展示REDUCE-It冠狀動脈疾病亞分析的新證據，突出了VASCEPA/VAZKEPA在二級預防患者中的益處，無論是否有冠狀動脈疾病史。"
Dr. Ketchum further added, "Additional data to be featured at the AHA Scientific Sessions include research highlighting the mechanistic effects of EPA, particularly its antioxidant effects in endothelial cells and the ability of EPA to impact the oxidation of Lp(a) particles. High Lp(a) concentrations are associated with increased CV event risk, and people with high levels face a 2-4 times greater risk of having an early event. With about 20% of the global population affected, research is crucial for understanding and addressing elevated Lp(a)."
凱徹姆博士進一步補充說，"在AHA科學會議上展示的額外數據包括突出EPA的機械作用的研究，尤其是其在內皮細胞中的抗氧化作用以及EPA影響Lp(a)顆粒的氧化的能力。高Lp(a)濃度與增加的心血管事件風險相關，高水平的人面臨早期事件風險增加2-4倍。全球人口約20％受影響，研究對於了解和解決高Lp(a)問題至關重要。"
譯文內容由第三人軟體翻譯。